2024-09-03 - Analysis Report
##  ABBV Stock Analysis Report

**Company Overview:**  ABBV is AbbVie Inc., a global pharmaceutical company specializing in research, development, and commercialization of innovative medicines across various therapeutic areas.

**Performance Analysis:**

**1.  Performance vs. S&P 500 (VOO):**

* **Cumulative Return:** ABBV (106.38%) outperformed VOO (89.66%) by 16.72%.
* **Relative Strength:** ABBV's current relative strength stands at 65.53%, indicating a significant outperformance compared to the historical range of its performance relative to VOO.

**2.  Recent Price Movement:**

* **Closing Price:** $196.31
* **5-day Moving Average:** $196.05
* **20-day Moving Average:** $193.17
* **60-day Moving Average:** $179.48
* **Analysis:** ABBV is currently trading slightly above its 5-day and 20-day moving averages, indicating a short-term uptrend. However, its price remains significantly above its 60-day moving average, suggesting a strong uptrend in the longer term.

**3.  Technical Indicators:**

* **RSI (Relative Strength Index):** 74.27.  ABBV is currently in overbought territory, suggesting potential for a short-term correction.
* **PPO (Percentage Price Oscillator):** -0.36. Negative value suggests a short-term downtrend, potentially aligning with the RSI overbought signal.
* **Delta_Previous_Relative_Divergence:** -3.27. A negative value indicates a recent downward shift in relative strength, further supporting the possibility of a short-term correction.
* **Expected Return:** 16.29%. This represents a potential maximum return over the next 5 years based on current investment levels.

**4.  Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |
| 2023-07-27 | 2.91 | 2.79 |

**Analysis:** ABBV has consistently exceeded earnings expectations in recent quarters, demonstrating strong financial performance and growth. The most recent earnings report (2024-07-25) showed an EPS of 2.65, exceeding the expected 2.57. This suggests a continued positive trend in ABBV's financial performance. 

**5.  Overall Analysis:**

ABBV has consistently outperformed the market, displaying strong growth and profitability. However, current technical indicators suggest a potential for a short-term correction. This is partially driven by the overbought nature of the stock, as indicated by the high RSI and recent decline in relative strength.  Despite the potential short-term correction, ABBV's long-term outlook remains positive, supported by its strong financial performance and consistent exceeding of earnings expectations.

**Disclaimer:** This analysis is for informational purposes only and should not be considered financial advice. It is crucial to conduct thorough research and consult with a financial advisor before making any investment decisions.